| HOME >> MEDICINE >> TECHNOLOGY |
Capacity expansion related charges reported in Cost of products sold include start-up charges related to manufacturing capacity expansion in India.(F)
Other restructuring charges: $7.8 million reported in Restructuring, impairment and (gain) on disposition of assets, net for distribution contract termination charges related to certain Latin America operations.(G)
Goodwill impairment: $155.0 million reported in Restructuring, impairment and (gain) on disposition of assets, net related to Hospira's EMEA reporting unit.(H)
Settlement of IRS tax audit benefit of $19.7 million reported in Income tax expense. This discrete income tax benefit is related to the completion and effective settlement of U.S. tax return audits.Nine months ended September 30, 2010 Reconciliation of GAAP to Non-GAAP Financial Measures:Gross Profit (1)Income From
OperationsNet Income (2)Diluted EPSGAAP financial measures$
,166.5$
465.6$
296.6$
.75Specified items: Project Fuel and related charges (A)
12.116.46.50.04 Facilities Optimization charges (B)
7.29.26.30.04 Amortization of certain intangible assets (C)
50.650.634.40.20 Certain quality and product related charges (D)
40.940.925.70.15 Acquisition and integration-related charges (E)
0.618.111.40.07 Research and development charge (F)
-27.517.20.10 Litigation settlement and related charges (G)
-14.08.50.05 Loss on early debt extinguishment (H)
--22.90.14Adjusted financial measures (3)
$
,277.9$
42.3$
429.5$
2.54GAAP results for the nine months ended September 30, 2010 include:(A)
Project Fuel and related charges: $12.1 million reported in Cost of products sold, $5.6 million reported in Restr
'/>"/>
| SOURCE Hospira, Inc. Copyright©2010 PR Newswire. All rights reserved |